CEO...Mark Diamond stated that Atl1102 was at an advanced stage and
As previously advised, the Company continues to seek a new partner to further develop ATL1102 for the multiple sclerosis indication. It is the Company’s view that this new indication in stem cell mobilization enhances the commercial value of ATL1102 and its attractiveness to a wider range of potential future partners.
Could this be one of the announcements before XMAS?
technicals, page-19
-
- There are more pages in this discussion • 138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |